Ionis Targets Ultra-Rare Disease Market With Zilganersen

 
• By Alaric DeArment
  
Ionis announced positive results from its Phase I-III study of zilganersen in Alexander disease. (Shutterstock)

More from Clinical Trials

More from R&D